By analogy, BRCAness cancers, i.e., those that share molecular features of germline BRCA1 or BRCA2 mutated cancers (gBRCAm), also phenocopy the platinum-salt or poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor sensitivity seen in gBRCAm cancers (21–23). This evidence concerns the gene BRCA2 and cancer.